Sector
PharmaceuticalsOpen
₹31.25Prev. Close
₹33.28Turnover(Lac.)
₹0.46Day's High
₹36.7Day's Low
₹31.2552 Week's High
₹52.152 Week's Low
₹27.33Book Value
₹16.02Face Value
₹10Mkt Cap (₹ Cr.)
20.99P/E
78.66EPS
0.41Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 6.51 | 6.51 | 6.51 | 6.51 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3.61 | 3.19 | 2.86 | 2.05 |
Net Worth | 10.12 | 9.7 | 9.37 | 8.56 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 56.64 | 59.94 | 71.83 | 81.15 |
yoy growth (%) | -5.52 | -16.54 | -11.48 | 415.22 |
Raw materials | -46.72 | -49.45 | -57.11 | -65.41 |
As % of sales | 82.49 | 82.5 | 79.5 | 80.6 |
Employee costs | -3.35 | -3.97 | -2.8 | -3.05 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 0.92 | -1.16 | 1.65 | 1.22 |
Depreciation | -0.27 | -0.29 | -0.2 | -0.2 |
Tax paid | -0.09 | 0.43 | -0.48 | -0.27 |
Working capital | 0.39 | 0.42 | 1.51 | 1.49 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -5.52 | -16.54 | -11.48 | 415.22 |
Op profit growth | -230.72 | -145.92 | 27.25 | 629.77 |
EBIT growth | -188.2 | -162.5 | 31.24 | 237.93 |
Net profit growth | -213.53 | -162.95 | 22.29 | 459 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director & CEO
Sanjeev Kumar
Non Executive Director
Him Jyoti
Whole Time Director
Sanjay Dhir
Independent Director
Anurag Malhotra
Independent Director
Kuldeep Singh
Company Sec. & Compli. Officer
Manju Bala
Plot No 194-195 3rd Flr Pha-II,
Industrial Area Ram Darbar,
Chandigarh - 160002
Tel: 91-172-4651105/3920738
Website: http://www.zenlabsethica.com
Email: preetremedies@gmail.com ; queries@zenlabsethica.co
E-2/3 Saki Vihar Rd,
Ansa Indl Estate, Saki Naka Andheri-E,
Mumbai - 400 072
Tel: 91-22-40430200
Website: www.bigshareonline.com
Email: info@bigshareonline.com
Summary
Zenlabs Ethica Limited (Formerly known Neelkanth Technologies Limited) was incorporated in 1993. The Company is one of the top 10 pharmaceutical contract marketing and trading companies in India that ...
Read More
Reports by Zenlabs Ethica Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.